Synmosa Biopharma (ROCO:4114) Accounts Payable: NT$553 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4114 Synmosa Biopharma Corp ROCO:4114
83 GF Score
Price NT$29.25
GF Value NT$32.89
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Synmosa Biopharma Accounts Payable?

Synmosa Biopharma ROCO:4114 +1.04% 83 Accounts Payable is NT$553 Mil as of Mar. 2026. GuruFocus rates ROCO:4114 with a GF Score™ of 83/100 and a GF Value™ of NT$32.89 (Modestly Undervalued). The stock has 1 warning sign investors should review.

Synmosa Biopharma's Accounts Payable for the quarter that ended in Mar. 2026 was NT$553 Mil.

Synmosa Biopharma's quarterly Accounts Payable declined from Sep. 2025 (NT$560 Mil) to Dec. 2025 (NT$558 Mil) and declined from Dec. 2025 (NT$558 Mil) to Mar. 2026 (NT$553 Mil).

Synmosa Biopharma's annual Accounts Payable increased from Dec. 2023 (NT$420 Mil) to Dec. 2024 (NT$468 Mil) and increased from Dec. 2024 (NT$468 Mil) to Dec. 2025 (NT$558 Mil).

Synmosa Biopharma Accounts Payable Related Terms

Synmosa Biopharma Accounts Payable Historical Data

* Premium members only.

The historical data trend for Synmosa Biopharma's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Synmosa Biopharma Accounts Payable Chart

Synmosa Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 248.60 429.68 420.29 468.43 558.36

Synmosa Biopharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 510.96 534.84 560.28 558.36 552.65
ROCO:4114
83GF Score
Synmosa Biopharma Corp ROCO:4114
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Synmosa Biopharma Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of NT$553 Mil mean?
Synmosa Biopharma (ROCO:4114) has a Accounts Payable of NT$553 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Synmosa Biopharma and its competitors.
Is Synmosa Biopharma's Accounts Payable too high?
Synmosa Biopharma's current Accounts Payable is NT$553 Mil. Overall, Synmosa Biopharma has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Synmosa Biopharma's Accounts Payable compare to ZTS?
Synmosa Biopharma's Accounts Payable of NT$553 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Drug Manufacturers company?
A good Accounts Payable depends on the Drug Manufacturers industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Synmosa Biopharma and its competitors. Synmosa Biopharma's current Accounts Payable is NT$553 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Synmosa Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Synmosa Biopharma (ROCO:4114) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$32.89, compared to a current price of NT$29.25 — trading 11.1% below its estimated fair value. The current Accounts Payable is NT$553 Mil. Synmosa Biopharma's overall GF Score™ is 83/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Synmosa Biopharma (ROCO:4114), the current Accounts Payable is NT$553 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Synmosa Biopharma (ROCO:4114) Overvalued in 2026?

Based on GuruFocus' analysis, Synmosa Biopharma stock appears to be undervalued. The current stock price of NT$29.25 is trading 11.1% below its estimated GF Value™ of NT$32.89. GuruFocus considers Synmosa Biopharma to be Modestly Undervalued.

Key valuation signals for ROCO:4114:

  • Accounts Payable: NT$553 Mil
  • GF Value™: NT$32.89 vs. price of NT$29.25 (11.1% below fair value)
  • GF Score™: 83/100 with 1 warning sign

No single metric tells the full story. See the ROCO:4114 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Synmosa Biopharma Business Description

Address No. 6, Gongye 1st Road, Hukou Township, Hsinchu County, Hsinchu, TWN
Synmosa Biopharma Corp is engaged in pharmaceuticals and medical devices, cosmetics, animal drugs, chemical food additives, beverages manufacturing and sales, and environmental drugs wholesale (retail), as well as the import and export of related businesses. Its segments include the Active Pharmaceutical Ingredients segment and the Generic Drugs segment. The Generic Drugs segment derives the majority of the revenue.
83GF Score

Get the complete analysis for ROCO:4114

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$29.25
Price
NT$32.89
GF Value